| 主权项 |
1. A method of treating a cancer that is responsive to an antimetabolite or antimitotic anti-cancer agent in a mammalian subject afflicted with the cancer, the method comprising:
administering to the subject at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a selective superoxide dismutase mimetic to potentiate the therapeutic effect of the anti-cancer agent(s); wherein the antimetabolite anti-cancer agent is selected from the group consisting of 2-fluorodeoxycytidine, 3′-azido-3′-deoxythymidine, 3′-deoxy-3′-deoxythymidin-2′-ene, 3′-dideoxycytidin-2′-ene, 3-fluoro-3′-deoxythymidine, 5-fluorocytosine, 5-fluorouracil, 5-methylcytosine, 5-propynylcytosine, 5-propynylthymine, 5-propynyluracil, 6-azauridine, 6-mercaptopurine, 8-aza-adenosine, 8-aza-guanosine, 8-fluoro-adenosine, acyclovir, allopurinol, ancitabine, arabinosyl adenine, azacitidine, azathiprine, bromouracil, capecitabine, carmofur, chlorouracil, cladribine, cytarabine, cytosine arabinoside, denopterin, deoxycoformycin, dideoxyuridine, dihydrouracil, doxifluridine, enocitabine, floxuridine, fludarabine, gancylovir, gemcitabine, methotrexate, pemetrexed, pentostatin, pteropterin, raltitrexed, thiamiprine, thioguanine, trimetrexate, salts thereof, and combinations thereof; the antimitotic anti-cancer agent is selected from the group consisting of docetaxel, epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, paclitaxel, vinblastine, vincristine, vindesine, vinorelbine, salts thereof, and combinations thereof; wherein the selective superoxide dismutase mimetic has no significant activity toward hydrogen peroxide and corresponds to Formula (4419): wherein X and Y are ligands. |
